Medco Health Solutions news from FiercePharma
News
New drug-spending leader: Diabetes
New data on pharma sales details some big shifts in spending. Diabetes meds have displaced cholesterol drugs as the Read more...
ALSO NOTED: FDA lifts ban on Watson plant in FL; Sanofi bolstered profits but lost in drug trial;
> Watson Pharmaceuticals finally saw the FDA lift its ban on new products from a Florida manufacturing plant, allowing drugs made there to be eligible for agency approval; the facility had been Read more...
ALSO NOTED: High-dose Celebrex triples heart risk; Actos slows plaque buildup in arteries;
> Patients taking the largest dose of Pfizer's painkiller Celebrex, 400 mg twice a day, tripled their chance of heart attack or stroke compared with placebo, according to a new study presented at Read more...
ALSO NOTED: Korea fines pharma firms for kickbacks; Medco boosts profits 16 percent;
> Ten Korean drug makers were fined $22 million for illegal rebates to hospitals and wholesalers. Report > Read more...
Younger patients pop more cardio meds
Whippersnappers are getting a jump on Grandpa. They're using cholesterol and blood pressure meds earlier and earlier--so much so that growth in sales to young folks is outpacing the growth of sales Read more...
Medco buys Polymedica for $1.5B
Medco Health Solutions hopes that what's good for diabetes patients is also good for its bottom Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets